Results 41 to 50 of about 177,775 (151)

Immune Response Checkpoint Inhibitors: New Risks of a New Class of Antitumor Agents

Безопасность и риск фармакотерапии, 2020
The introduction into clinical practice of immune checkpoint inhibitors that block cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein-1 (PD-1), and programmed cell death ligand-1 (PD-L1), has improved the prognosis of ...
E. V. Shubnikova, T. M. Bukatina, N. Yu. Velts, D. A. Kaperko, G. V. Kutekhova   +4 more
doaj   +1 more source

Cardiotoxicity of immune checkpoint inhibitors

ESMO Open, 2017
Cardiac toxicity after conventional antineoplastic drugs (eg, anthracyclines) has historically been a relevant issue. In addition, targeted therapies and biological molecules can also induce cardiotoxicity. Immune checkpoint inhibitors are a novel class of anticancer drugs, distinct from targeted or tumour type-specific therapies.
VARRICCHI, GILDA, GALDIERO, MARIA ROSARIA, MARONE, GIANCARLO, CRISCUOLO, GJADA, TRIASSI, MARIA, BONADUCE, DOMENICO, MARONE, GIANNI, TOCCHETTI, CARLO GABRIELE   +7 more
openaire   +3 more sources

PD-1 Blockade Promotes Emerging Checkpoint Inhibitors in Enhancing T Cell Responses to Allogeneic Dendritic Cells

Frontiers in Immunology, 2017
Immune checkpoint inhibitors, which target coinhibitory T cell molecules to promote anticancer immune responses, are on the rise to become a new pillar of cancer therapy.
Carmen Stecher, Claire Battin, Judith Leitner, Markus Zettl, Katharina Grabmeier-Pfistershammer, Christoph Höller, Gerhard J. Zlabinger, Peter Steinberger   +7 more
doaj   +1 more source

The Future of Checkpoint Inhibitors in Uveal Melanoma: A Narrative Review

Ophthalmology and Therapy
Introduction Immune checkpoint inhibitors have made tremendous progress over the last decade in the treatment of cutaneous melanoma, but their application in uveal melanoma treatment is less successful, owing in part to the immunological privilege of the
Jinyu Wang, Zehua Li, Hongbo Yin
doaj   +1 more source

Progress of Biomarkers to Predict Response to Immune Checkpoint Inhibitors in Microsatellite Stability Colorectal Cancer

Zhongliu Fangzhi Yanjiu, 2023
The exploration of biomarkers predicting response to immune checkpoint inhibitors in microsatellite stability colorectal cancer can enable more patients to benefit from immunotherapy.
WANG Zhiqiang, DONG Shuai, LI Menglong, LIANG Rui   +3 more
doaj   +1 more source

Immune escape mechanisms and therapeutic approaches in cancer: the cancer-immunity cycle

Therapeutic Advances in Medical Oncology, 2022
The introduction of immune checkpoint inhibitors has changed the therapeutic possibilities for various cancer types. However, despite the success in some entities, a significant fraction of patients does not respond to immune checkpoint inhibitors.
Angelika M. Starzer, Matthias Preusser, Anna S. Berghoff   +2 more
doaj   +1 more source

SnapShot: Immune Checkpoint Inhibitors

Cancer Cell, 2017
Immunotherapy has changed the landscape of cancer treatment. Checkpoint blockade therapies unleash breaks in the immune system and induce long-lasting responses. However, a significant number of patients do not respond (innate resistance), and a subset progress after responding (acquired resistance).
Abril-Rodriguez, Gabriel, Ribas, Antoni
openaire   +4 more sources

The role of kidney biopsy in immune checkpoint inhibitor nephrotoxicity

Frontiers in Medicine, 2022
Immune checkpoint inhibitors, medications that boost host immune response to tumor cells, are now at the forefront of anti-cancer therapy. While efficacious in the treatment of patients with advanced cancer, immune checkpoint inhibitors can lead to ...
Emily M. Moss, Mark A. Perazella, Mark A. Perazella   +2 more
doaj   +1 more source

Research progress of targeted therapy combined with immunotherapy for hepatocellular carcinoma

Frontiers in Oncology, 2023
Hepatocellular carcinoma is a common gastrointestinal malignancy with a high mortality rate and limited treatment options. Molecularly targeted drugs combined with immune checkpoint inhibitors have shown unique advantages over single-agent applications ...
Shuqi Xie, Mengchao Wang, Chuanxiu Zeng, Yan Ou, Lu Zhao, Dong Wang, Liwei Chen, Fanming Kong, Dan Yi   +8 more
doaj   +1 more source

Nephrotic syndrome with acute kidney injury due to combination therapy of immune checkpoint inhibitors: a case report and review of the literature

BMC Nephrology
Background Recent studies have focused on immune checkpoint inhibitors. Renal complications associated with the use of immune checkpoint inhibitors are uncommon compared with other immune-related adverse events.
Ryosuke Saiki, Kan Katayama, Haruko Saiki, Ayumi Fukumori, Kayo Tsujimoto, Masahiro Yamawaki, Fumika Tanaka, Daisuke Takahashi, Keiko Oda, Yasuo Suzuki, Tomohiro Murata, Kaoru Dohi   +11 more
doaj   +1 more source